WW International (WW) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 6, 2025, with shareholders able to vote and submit questions electronically.
Shareholders will vote on electing three Class III directors, ratifying the external auditor, and an advisory say-on-pay vote for executive compensation.
Only shareholders of record as of April 2, 2025, are eligible to vote.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposals include electing three Class III directors, ratifying PricewaterhouseCoopers as auditor, and an advisory vote on executive compensation.
Shareholders may submit additional proposals for the 2026 meeting by December 22, 2025.
Voting can be done online, by phone, mail, or during the virtual meeting; beneficial owners must obtain a legal proxy to vote at the meeting.
Board of directors and corporate governance
The Board consists of seven members divided into three classes, with staggered three-year terms.
All Board committees (Audit, Compensation, NCG) are composed of independent directors.
Corporate Governance Guidelines, committee charters, and a Code of Business Conduct and Ethics are in place and reviewed regularly.
The Board separates the roles of CEO and Chairman, with Thilo Semmelbauer serving as Chairman.
The NCG Committee oversees ESG plans and board composition.
Latest events from WW International
- Clinical growth and transformation drive higher ARPU as behavioral business declines.WW
Q4 202516 Mar 2026 - Q2 2024 revenue fell 10.9% as clinical subscribers surged 120% and cost savings were targeted.WW
Q2 20242 Feb 2026 - Q3 revenue and subscribers fell, but clinical growth and cost actions supported margin gains.WW
Q3 202416 Jan 2026 - GLP-1 integration, financial restructuring, and targeted programs drive innovation and growth.WW
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - Clinical growth and cost cuts offset declines, but bankruptcy and high debt loom.WW
Q1 202514 Jan 2026 - Q4 profit returned as clinical growth and cost actions offset revenue and subscriber declines.WW
Q4 20241 Dec 2025 - Debt cut by $1.15B, leverage below 3x, and operations continue during reorganization.WW
Investor Update25 Nov 2025 - Debt cut to $465M, Q2 revenue $189M, Clinical up 55%, 2025 guidance $685M–$700M.WW
Q2 202523 Nov 2025 - Clinical revenue up 35% and clinical subscribers up 59.6% as debt fell 70% post-bankruptcy.WW
Q3 202513 Nov 2025